Abstract 5942
Background
Fatigue represents a complex and frequent symptom in cancer patients and influences their quality of life. Although nurses consider the initial evaluation of the patient to be fundamental, this problem is underestimated in clinical practice and often leads to under-treatment. In addition, the patients and their families still often do not report the symptom because they fear that it will lead to a reduction or suspension of treatment or they think that the symptom is inevitable.
Methods
Mixed methods study. Data were collected using Brief Fatigue Inventory, patients’ interviews, focus groups with nurses and analysis of patients’ records. The setting is represented by two impatient departments of Oncology Institute of Southern Switzerland. Quantitative data were analysed with SPSS 22.0. For the interviews and focus groups, the analysis processes were conducted according to conventional content analysis using Nvivo 10 software.
Results
71 questionnaires were analysed, 39 males and 32 females. The mean age was 65,7±14 years. Fatigue was reported 5 times (7%) in nursing documents and 17 times problems fatigue was reported by nurses 5 times (7%) in patients’ records, while in 17 cases (23.9%) related problems were reported. 12 patients were interviewed. Five themes were identified: feeling powerless and aggressive, my strategies or what helps me, feeling reassured by the presence of family members, feeling reassured by nurses’ gesture, to be informed. Three themes were identified from nurses focus group: objectivity and subjectivity in the assessment of asthenia, nursing contribution in the multidisciplinary management of asthenia and difficulty in evaluating outcomes.
Conclusions
A not systematic approach to the management of fatigue emerges. Patients are satisfied with the care received but would like more information and specific interventions. Quantitative and qualitative results seem converge. Fatigue is still an underestimated problem in clinical practice. Specific training interventions for health professionals are needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Scientific Research Advisory Board (ABREOC).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4506 - Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity
Presenter: Adel Samson
Session: Poster Display session 3
Resources:
Abstract
1631 - Randomized phase 2 clinical trial of NY-ESO-1 protein vaccine combined with cholesteryl pullulan (CHP-NY-ESO-1) in resected esophageal cancer patients
Presenter: Shinichi Kageyama
Session: Poster Display session 3
Resources:
Abstract
4244 - T cell repertoire sequencing reveals dynamics of response to dendritic cell vaccine plus dasatinib for checkpoint blockade resistant metastatic melanoma
Presenter: Luca Quagliata
Session: Poster Display session 3
Resources:
Abstract
5791 - Ixovex, a novel oncolytic E1B-mutated adenovirus
Presenter: Mohiemen Anwar
Session: Poster Display session 3
Resources:
Abstract
4170 - Anti-CSPG4 DNA vaccination as a promising strategy for the treatment of CSPG4+ tumors: a comparative oncology trial
Presenter: Federica Riccardo
Session: Poster Display session 3
Resources:
Abstract
5780 - Antitumor activity, immunogenicity and safety of a novel PD-1 vaccine in combination with two chimeric HER-2 peptide vaccine in syngeneic Balb/c, C57Bl/6 models and in beagle dogs
Presenter: Pravin Kaumaya
Session: Poster Display session 3
Resources:
Abstract
5860 - Maternal immunization against ALK as a weapon to fight neuroblastoma
Presenter: Giuseppina Barutello
Session: Poster Display session 3
Resources:
Abstract
4720 - Phase 1 study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumors
Presenter: Jason Luke
Session: Poster Display session 3
Resources:
Abstract
5717 - Anti-PD-L1/IL-15 fusion protein generates robust adaptive immune gene signatures in tumors leading to tumor inhibition and memory responses
Presenter: Stella Martomo
Session: Poster Display session 3
Resources:
Abstract
1802 - Evaluation of the anti-tumor efficacy and immune effects of N-809, a novel IL-15 superagonist/anti-PD-L1 bispecific agent
Presenter: Kristin Hicks
Session: Poster Display session 3
Resources:
Abstract